Maze Therapeutics, Inc.
As of Oct 22, 2026, Maze Therapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $31.95, 38.4% below its 52-week high and below its 200-day average, which is falling.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MAZE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MAZE among Biotechnology158th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …158 | MAZE | Stage 4 · wk 6 | 61 | +13.7% |
Maze Therapeutics: quick answers
What stage is Maze Therapeutics in?
As of Oct 22, 2026, Maze Therapeutics (MAZE) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean
Is Maze Therapeutics in an uptrend?
No. Maze Therapeutics is in a Stage 4 downtrend. It trades 0.5% below its 200-day average, which is falling.
How far is Maze Therapeutics from its 52-week high?
Maze Therapeutics closed at $31.95 on Oct 22, 2026, 38.4% below its 52-week high of $51.84. Its 52-week low is $22.39.
How has Maze Therapeutics performed over the past year?
As of Oct 22, 2026, Maze Therapeutics is up 8.2% over the past year and down 19.7% so far in 2026.
Which sector and industry is Maze Therapeutics in?
Maze Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.